-transparent.png){kind=logo}
A number of serine/threonine kinase receptors have recently been identified. Most of the members of this family are type I or type II receptors for proteins in the transforming growth factor-beta (TGF-beta) superfamily. The type I and type II receptors form heteromeric receptor complexes after binding of the ligands, and transduce intracellular signals. TGF-beta type I receptor needs type II receptor for ligand binding, and type II receptor needs type I receptor for signalling. The signal transducing molecules that interact with heteromeric serine/threonine kinase receptor complexes remain to be elucidated; cyclin-dependent kinases and the retinoblastoma protein appear to be downstream elements in the antiproliferative pathway of TGF-beta.
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
January 2000,
Leukemia,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
April 1991,
Oncogene,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
June 1997,
Current opinion in genetics & development,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
December 1998,
Seikagaku. The Journal of Japanese Biochemical Society,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
January 1988,
Cold Spring Harbor symposia on quantitative biology,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
August 1997,
Development (Cambridge, England),
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
December 2009,
CNS & neurological disorders drug targets,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
December 2008,
The Journal of biological chemistry,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
August 1999,
Nihon rinsho. Japanese journal of clinical medicine,
K Miyazono, and
P ten Dijke, and
H Yamashita, and
C H Heldin
April 2002,
The EMBO journal,
